57th ASH Annual Meeting and Exposition (December 5-8, 2015): 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Sensitivity and Resistance Mechanisms

Myeloma: Biology and Pathophysiology, excluding Therapy Oral and Poster Abstracts
Oral

W224ABEF, Level 2 (Orange County Convention Center)

Moderators:

Masood A Shammas, PhD, VA Boston Healthcare System and Babatunde O. Oyajobi, MBBS, PhD, MBA, University of Texas Health Science Center at San Antonio

Disclosures:

No relevant conflicts of interest to declare.

7:00 AM

499

47 Genes Define Myeloma Cell Acquired Resistance to Bortezomib and Have Profound Prognostic Implications in Multiple Myeloma

Xenofon Papanikolaou, MD^*, Caleb K. Stein, MS^*, Ricky D Edmondson, Ph.D.^*, Veronica Macleod^*, Ruslana Tytarenko^*, Bart Barlogie, MD, PhD, Joshua Epstein, DSc and Christoph Heuck, MD

Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR

7:15 AM

500

Inhibition of CDK4/CDK6 Sensitizes Myeloma to IMiD By Reducing the MEIS2 to Cereblon Ratio That Accelerates IKZF1 and IKZF3 Degradation

Xiangao Huang, PhD^1,2^*, David Jayabalan, BSMS, MSc^1,3^*, Maurizio Di Liberto, PhD^1,2, Zhengming Chen, PhD⁴^*, Anna C Schinzel, PhD⁵^*, Scott Ely, MD, MPH^1,2, Adriana C Rossi, MD, MHS³, Roger N Pearse, MD, PhD³^*, Ekta Aneja, MBBS¹^*, Morton Coleman, MD³^*, Joseph M Lane, MD⁶^*, William C. Hahn, MD, PhD⁵^*, Tomer M Mark, MD, MSc³, Ruben Niesvizky, MD³ and Selina Chen-Kiang, PhD^1,2,7

¹Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY
²Meyer Cancer Center, Weill Cornell Medical College, New York, NY
³Center of Excellence for Lymphoma and Myeloma, Weill Cornell Medical College, New York, NY
⁴Department of Public Health, Weill Cornell Medical College, New York, NY
⁵The Broad Institute of Harvard and MIT, Boston, MA
⁶Hospital for Special Surgery, New York, NY
⁷Graduate Program in Immunology and Microbial Pathogenesis, Weill Cornell Medical College, New York, NY

7:30 AM

501

A Multidisciplinary Model Predicts Clinical Response in Relapsed Multiple Myeloma

Kenneth H. Shain, MD, PhD¹, Ariosto Silva, Ph.D.²^*, Mark B Meads, PhD³^*, Allison Distler, B.S.³^*, Timothy Jacobson, B.S.⁴^*, Robert Gatenby, M.D., Ph.D.²^*, Rachid Baz¹, Maria Silva, M.Sc⁵^*, Dmitri Rebatchouk, Ph.D.⁶^* and Chris Cubitt, Ph.D.⁵^*

¹Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
²Intergrated Mathematical Oncology, Moffitt Cancer Center, Tampa, FL
³Malignant Hematology, Moffitt Cancer Center, Tampa, FL
⁴Intergrated Mathematic Oncology, Moffitt Cancer Center, Tampa, FL
⁵Moffitt Cancer Center, Tampa, FL
⁶nPharmakon, Piscataway, NJ

7:45 AM

502

Characterization of the Role of Regulatory T Cells (Tregs) in Inducing Progression of Multiple Myeloma

Yawara Kawano, MD, PhD¹^*, Michele Moschetta, MD¹^*, Katsutoshi Kokubun, PhD¹^*, Pavlo Lukyanchykov, MD²^*, Esilida Sula Karreci, MD²^*, Salomon Manier, MD¹, Shokichi Tsukamoto, MD, PhD¹, Satoshi Takagi, PhD¹, Jiantao Shi³^*, Michaela R. Reagan, PhD⁴, Daisy Huynh, BS, MS¹^*, Antonio Sacco, BS¹^*, David M. Dorfman, MD, PhD⁵, Marta Chesi, PhD⁶, Peter Leif Bergsagel, MD, PhD⁷, Aldo M Roccaro, MD, PhD¹, Jamil Azzi, MD²^* and Irene M. Ghobrial, MD⁸

¹Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
²Transplantation Research Center, Renal Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
³Biostatistics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁴Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁵Department of Pathology, Brigham and Women's Hospital, Boston, MA
⁶Mayo Clinic, Scottsdale, AZ
⁷Comprehensive Cancer Center, Mayo Clinic, Scottsdale, AZ
⁸Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA

8:00 AM

503

Defining Primary Marrow Microenvironment-Induced Synthetic Lethality and Resistance for 2,684 Approved Drugs Across Molecularly Distinct Forms of Multiple Myeloma

Megan Murnane, M.Sc.¹^*, Eugen Dhimolea, PhD²^*, Ruojing Li, BS³^*, Megan A. Bariteau, BSc²^*, Diamond D. Wheeler, BS⁴^*, Rosemary J. Akhurst, PhD⁵^*, Aaron C. Logan, MD, PhD⁶, Pamela Munster, M.D.⁷^*, Arun Wiita, MD, PhD⁴^*, Thomas G. Martin III, MD¹, Jeffrey L. Wolf, MD, PhD⁶, Jun O. Liu, PhD³^*, Constantine S. Mitsiades, MD, PhD⁸ and Blake T. Aftab, PhD⁹

¹Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA
²Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
³Department of Pharmacology & Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD
⁴Department of Laboratory Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA
⁵Department of Anatomy, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA
⁶University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
⁷Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA
⁸Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁹Dept. of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA

8:15 AM

504

Identification of a Novel Long Intergenic Noncoding RNA - Linc00936, with Significant Impact on Multiple Myeloma Cell Growth Via mTOR Pathway Inhibition

Annamaria Gulla, MD^1,2^*, Mehmet Kemal Samur, PhD³^*, Mariateresa Fulciniti, PhD⁴^*, Masood A Shammas, PhD^5,6, Teru Hideshima, M.D., Ph.D.⁴, Pierosandro Tagliaferri, MD²^*, Giovanni Parmigiani, PhD³^*, Pierfrancesco Tassone, MD²^*, Kenneth C Anderson, MD⁵ and Nikhil C. Munshi, MD^6,7

¹Jerome Lipper Multiple Myeloma Disease Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA
²Salvatore Venuta Campus, Magna Graecia University, Catanzaro, Italy
³Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA
⁴Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁵The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁶VA Boston Healthcare System, West Roxbury, MA
⁷Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, MA

See more of: Myeloma: Biology and Pathophysiology, excluding Therapy
See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

651A.O3.6 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Sensitivity and Resistance Mechanisms